Dendritic cell and T-lymphocytes, illustration

Johns Hopkins Researchers Refine TMB Calculations of Immunotherapy Response

The team developed a computational approach to estimate corrected TMB values for each tumor by simulating 20,000 tumors with various levels of TMB and sequencing coverage using information from the Cancer Genome Atlas to generate a correction factor for each simulated tumor based on its purity.
Genetic testing concept, DNA icon, medical doctor, isolated on white

ArcherDX’s Personalized Cancer Monitoring (PCM) Tech Gets FDA Breakthrough Device Designation

Breakthrough device designation is designed to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment, and review, while preserving FDA standards.
Fabric Genomics is partnering with data management company ITTM to provide secure genomic data hosting capabilities for European customers. (Source: iStock/© evryka23)

Large Scale Genomic Study Uncovers New Disease Targets

Children’s Hospital of Philadelphia researchers compared the sequence data of more than 100,000 people of European ancestry and found copy number variant (CNV) associations in four major disease categories: autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases.
ersonal Genome Diagnostics (PGDx) said today that its 500+ gene pan-cancer tumor profiling tissue assay is being used by Merck & Co. in a Phase II clinical trial designed to assess patient response to a dual biomarker-directed precision oncology combination therapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC).

Amgen Taps Guardant, Qiagen for AMG 510 NSCLC Companion Dx Partnerships

The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.

LabCorp to Use New Thermo Fisher Genexus System for CDx, Oncology, Precision Medicine Applications

Once Genexus is validated, the automated platform could help accelerate access to next-generation sequencing (NGS) testing for clinical trials through LabCorp’s specialty and drug development central laboratories.

Illumina Debuts Two New Sequencers, Inks Dx Deal with Roche

The NextSeq 2000 and NextSeq 1000 are both designed to meet growing demand for clinical genomic data at reduced cost, while the collaboration with Roche is focused on advancing clinical diagnostics leveraging Illumina’s pan-cancer assay TruSight Oncology 500.
Color Genomics launched its $249 Color Test

Color to Collaborate with Sanford Health, Expand Northshore Partnership

Color will help Sanford move its Imagenetics genetic medicine program from an array-based platform to NGS testing, and will expand its partnership with NorthShore University HealthSystem—which has already enrolled 10K patients—to include 30 additional clinics.
Fluidigm and Genomenon plan to create a joint panel design offering intended to help researchers accelerate the design of disease-specific next-generation sequencing

Element Biosciences Raises $80M to Accelerate Development of a New DNA Sequencing Platform

Led by ex-Illumina executives, Element’s founders believe its sequencing technology can reduce costs and inject more competition into a market dominated by their former employer.

ArcherDx and Illumina to Partner, Co-Market In Vitro Diagnostics

The multi-year agreement covers co-marketing of future ArcherDX IVD tests used with the Illumina NextSeq 550Dx and MiSeq Dx Systems encompassing oncology testing—including companion diagnostics for therapeutic selection—personalized monitoring, and recurrence surveillance IVD tests.
Sea of US 1 dollar bills on yellow background

IsoPlexis’ $20M Financing to Enable Continued Commercial Expansion of its Single-Cell Platforms

The financing round comes as IsoPlexis pushes to expand its operational, manufacturing, and commercial team globally. Currently, the company has operations in the U.S., Europe, and Asia, with more than 130 employees.
Scroll Up